Medicare and Medicaid both provide drug coverage, but they operate under fundamentally different rules. For GLP-1 medications, the differences are especially stark: Medicare follows national rules that apply the same way in every state, while Medicaid varies dramatically by state — some states cover GLP-1s generously, others barely cover them at all.
If you are on one of these programs (or both), understanding these differences can save you thousands of dollars and months of frustration.
Key Differences at a Glance
| Feature | Medicare Part D | Medicaid |
|---|---|---|
| Rule structure | National (CMS rules apply uniformly) | State-by-state (each state sets its own formulary) |
| GLP-1 for diabetes | Covered on most plans | Covered in most states (Medicaid rebate program) |
| GLP-1 for obesity | Newly allowed under TREAT Act (2026) | Optional — states choose whether to cover |
| Out-of-pocket cost | Copays vary; $2,000 annual cap | $0–$4 in most states (nominal copays) |
| Prior authorization | Common; 7-day turnaround | Very common; turnaround varies by state |
| Formulary updates | Annual (during open enrollment) | Quarterly or as needed |
| Appeals process | 5-level federal process | State fair hearing process |
| Compounded GLP-1s | Not covered | Not covered (in any state) |
Medicare Part D: National Rules
Medicare Part D operates under federal rules set by the Centers for Medicare & Medicaid Services (CMS). While individual Part D plans have discretion over formulary design and tier placement, they must all operate within the same regulatory framework:
- Every plan must cover at least two drugs in each therapeutic category. For GLP-1 agonists, this means most plans cover at least Ozempic and one other GLP-1.
- The $2,000 annual out-of-pocket cap applies universally. No Part D plan can charge more than $2,000/year in total out-of-pocket costs, regardless of drug prices.
- Anti-obesity drug coverage is now permitted (not required) following the TREAT Act. Plans choose which obesity drugs to cover and under what conditions.
- Prior authorization criteria are plan-specific but must be reasonable and based on clinical guidelines.
- Appeals follow a standardized 5-level process with specific timelines at each level.
The uniformity of Medicare is its strength: a beneficiary in Florida has the same fundamental rights and cost protections as one in Oregon. The plan details differ, but the regulatory guardrails are identical.
Medicaid: The State-by-State Patchwork
Medicaid is jointly funded by the federal government and individual states, and each state designs its own drug benefit within broad federal guidelines. This creates enormous variation in GLP-1 coverage:
States Covering GLP-1s for Obesity (as of early 2026)
A growing number of state Medicaid programs cover GLP-1s for weight management, not just diabetes. States with confirmed obesity-indication GLP-1 coverage include:
- New York — covers Wegovy with prior authorization (BMI ≥30 or ≥27 with comorbidity)
- California (Medi-Cal) — added Wegovy to formulary in 2025; prior auth and step therapy through Contrave required first
- Massachusetts (MassHealth) — covers Wegovy and Zepbound with clinical criteria
- Minnesota — covers several anti-obesity medications including GLP-1s
- Washington — Apple Health covers Wegovy with extensive documentation requirements
- Colorado — added GLP-1 obesity coverage in 2025
- Connecticut — covers with prior authorization
States Not Covering GLP-1s for Obesity
Many states continue to exclude anti-obesity medications from their Medicaid formularies. Unlike Medicare, there is no TREAT Act equivalent forcing state Medicaid programs to cover these drugs. States with limited or no obesity-indication GLP-1 coverage include:
- Texas — covers GLP-1s for diabetes only; no obesity indication coverage
- Florida — limited coverage, diabetes indication only
- Georgia — no anti-obesity medication coverage
- Tennessee (TennCare) — diabetes-only GLP-1 coverage
- Mississippi — minimal anti-obesity drug coverage
- Alabama — no obesity-indication GLP-1 coverage
State formularies change frequently. Check your state's current preferred drug list (PDL) for the most up-to-date information.
Diabetes Coverage on Medicaid
For type 2 diabetes, the picture is better across the board. Under the Medicaid Drug Rebate Program, states must generally cover FDA-approved drugs from participating manufacturers. Since all major GLP-1 manufacturers participate in the rebate program, most state Medicaid programs cover at least one GLP-1 for diabetes — though preferred agents vary:
- Some states prefer Ozempic as the formulary GLP-1
- Others prefer Trulicity (often at a lower net cost after rebates)
- Mounjaro coverage for diabetes is expanding but not universal
- Rybelsus is available on some state formularies as an oral option
Dual Eligible Patients: Medicare + Medicaid
Approximately 12 million Americans are dual eligible — enrolled in both Medicare and Medicaid simultaneously. For these patients, GLP-1 coverage follows specific rules:
How Drug Coverage Works for Dual Eligibles
- Medicare Part D is the primary payer for prescriptions. If you are dual eligible, your drug coverage comes through a Medicare Part D plan (or the drug benefit in your Medicare Advantage plan), not through Medicaid.
- Medicaid wraps around Medicare. Medicaid may pay your Part D premiums and reduce or eliminate copays, but it does not typically provide separate drug coverage for drugs already available through Part D.
- You automatically qualify for Extra Help. Dual eligible beneficiaries receive the full Low Income Subsidy, which means copays of $0 for drugs below a cost threshold and no more than $4.50 for others (2026 amounts).
- No coverage gap. Dual eligibles skip the donut hole entirely and pay reduced copays throughout the year.
Practical Impact
For dual eligible patients, GLP-1 costs are typically $0–$4.50 per month. This applies to both diabetes-indication and (under the TREAT Act) obesity-indication GLP-1s that are on the Part D plan's formulary. The combination of Extra Help and Medicaid wrap-around coverage creates the lowest possible out-of-pocket cost for GLP-1 medications.
If you are dual eligible and having trouble accessing a GLP-1, the issue is almost always prior authorization, not cost. Work with your prescriber to ensure documentation meets Part D plan requirements.
Cost Comparison: Medicare vs. Medicaid
| Cost Factor | Medicare Part D | Medicaid | Dual Eligible |
|---|---|---|---|
| Monthly premium | $0–$100+ | $0 | $0 (Medicaid pays) |
| Annual deductible | Up to $590 | $0 in most states | $0 |
| GLP-1 copay | $47–$430/mo | $0–$4 | $0–$4.50 |
| Annual cap | $2,000 | None needed (costs already near $0) | $0 effective |
| Coverage gap impact | Eliminated by cap | N/A | N/A |
Prior Authorization Differences
Both programs use prior authorization, but the process differs substantially:
Medicare Part D Prior Auth
- Decision within 72 hours (expedited) or 7 calendar days (standard)
- 5-level federal appeals process with independent review at Level 2
- Plans must provide written denial with specific clinical rationale
- Relatively standardized criteria across plans
Medicaid Prior Auth
- Timelines vary by state (24 hours to 15 business days in some states)
- Appeals go through state fair hearing process (not federal)
- Criteria can be highly state-specific and may change with each formulary update
- Some states require prescriber to be a specific specialist type (endocrinologist, bariatric specialist)
How to Check Your Coverage
For Medicare Part D
- Go to Medicare.gov/plan-compare
- Enter your zip code and the medications you take
- Compare plans side by side for formulary coverage, tier placement, and estimated annual cost
- Or call 1-800-MEDICARE (1-800-633-4227)
For Medicaid
- Search for your state's Preferred Drug List (PDL) — usually found on your state Medicaid agency website
- Look up the specific GLP-1 medication and check both the diabetes and obesity sections
- Call your state's Medicaid member services line for coverage confirmation
- Ask your pharmacy to run a test claim to check real-time eligibility
Advocacy Resources
If you are denied GLP-1 coverage through either program, these resources can help:
- State Health Insurance Assistance Program (SHIP): Free counseling for Medicare issues — shiphelp.org
- Obesity Action Coalition: Patient advocacy organization that provides appeals letter templates and coverage guidance — obesityaction.org
- NeedyMeds: Database of patient assistance programs — needymeds.org
- Your state's legal aid organization: Can assist with Medicaid fair hearing appeals at no cost
- Patient advocate at your healthcare provider's office: Many clinics have staff dedicated to navigating insurance issues
Bottom Line
Medicare and Medicaid both cover GLP-1s for diabetes, but obesity coverage remains a patchwork. Medicare is moving toward broader coverage nationally thanks to the TREAT Act and the $2,000 annual cap makes costs manageable. Medicaid coverage depends entirely on your state — some states are generous, others provide nothing for weight management. Dual eligible patients have the best cost protection of any group, paying near-zero for covered medications.
The most important step is to check your specific coverage before assuming anything, and to appeal any denial — success rates are higher than most patients realize.
For more on Medicare GLP-1 coverage specifically, see our Medicare GLP-1 coverage overview and complete Part D guide.